Koo wrote "Seeing that "MACE can include both atherosclerotic events (MI and stroke) and CHF events," what's to prevent Hepalink from manufacturing Apabetalone in compliance with their licence agreement with Resverlogix?"

I don't see the connection between the first part of your post about MACE and the second part about Hepalink's licensing agreement. Why are you bringing up the Hepalink licensing agreement now? Can you please explain Koo? 

BDAZ